Objective-Hypercholesterolemia is an atherosclerotic condition that is associated with impaired neovascularization in response to ischemia. This study sought to define the role of microRNAs in that pathophysiology. Approach and Results-Next-generation sequencing and quantitative reverse transcription polymerase chain reaction analyses identified miR-150 as a proangiogenic microRNA, which expression is significantly reduced in the ischemic muscles of hypercholesterolemic apolipoprotein E-deficient (ApoE −/− ) mice, and in human umbilical vein endothelial cells exposed to oxidized low-density lipoprotein. Forced expression of miR-150 using a miR mimic could rescue oxidized low-density lipoprotein-mediated impairment of endothelial cell migration and tubule formation in vitro. In a mouse model of hindlimb ischemia, intramuscular injection of miR-150 mimic restored blood flow recuperation, vascular densities in ischemic muscles, and functional mobility in ApoE −/− mice. Treatment of ApoE −/− mice with miR-150 also increased the number and the activities of proangiogenic cells. miR-150 targets SRC kinase signaling inhibitor 1, an important regulator of Src (proto-oncogene tyrosine-protein kinase Src) activity. Here we found that hypercholesterolemia and oxidized low-density lipoprotein exposure are associated with increased SRC kinase signaling inhibitor 1 expression and decreased Src activity. However, treatment with miR-150 mimic reduces SRC kinase signaling inhibitor 1 expression and restores Src and downstream endothelial nitric oxide synthase and Akt (protein kinase B) activities both in vitro and in vivo. We also demonstrate the interrelation between miR-150 and SRC kinase signaling inhibitor 1 and their importance for endothelial cell angiogenic activities. Conclusions-Hypercholesterolemia is associated with reduced expression of miR-150, impaired Src signaling, and inefficient neovascularization in response to ischemia. Forced expression of miR-150 using a miR mimic could constitute a novel therapeutic strategy to improve ischemia-induced neovascularization in atherosclerotic conditions. Visual Overview-An online visual overview is available for this article. 
A fter ischemia, one of the most important physiological responses is the capacity to develop new blood vessels (neovascularization) to maintain the perfusion and the integrity of tissues. 1 Neovascularization necessitates the activation, the proliferation, and the migration of mature endothelial cells that will extend the preexisting vascular network (ie, angiogenesis). 2 In addition to angiogenesis, it has been demonstrated that postnatal neovascularization also depends on the action of bone marrow-derived proangiogenic cells (PACs). 3, 4 PACs have been shown to reach sites of ischemia where they promote neovascularization mainly through paracrine secretion of growth factors and cytokines. 5 Angiogenesis is modulated by the microenvironment and by different growth factors. Vascular endothelial growth factor (VEGF) has a critical rate-limiting role in this process, 6 and the tyrosine kinase Src (proto-oncogene tyrosine-protein kinase Src) has been shown to be required during VEGF-induced angiogenesis and vascular permeability. 7 Once activated, Src may in turn stimulate PI3K (phosphoinositide 3-kinase)/Akt (protein kinase B), a pathway that is involved in endothelial cell survival, migration, and angiogenesis. 8 Src also activates endothelial nitric oxide synthase (eNOS), 9 an enzyme that has been shown to have a crucial role for endothelial cell migration, VEGF-induced angiogenesis, and neovascularization after limb ischemia. 10, 11 It is now recognized that pathological conditions and risk factors involved in the development of atherosclerosis are also often associated with impaired neovascularization in response to ischemia. 1 Hypercholesterolemia, an important cardiovascular risk factor, has been shown to be associated with impaired blood flow recuperation and angiogenic response in several animal models. [12] [13] [14] Even in the absence of clinically apparent atherosclerotic diseases, hypercholesterolemia by itself was also shown to reduce the number and the function of PACs in patients. 15 However, the precise mechanisms responsible for the detrimental effects of hypercholesterolemia on vascular function, angiogenesis, and neovascularization are still largely unknown.
MicroRNAs (miRNAs) represent a novel class of endogenous noncoding small RNA molecules (20-25 nucleotides) that regulate a wide range of physiological and pathological processes. Although miRNAs are increasingly recognized as important factors involved in angiogenesis, 16, 17 their specific role for the modulation of ischemia-induced neovascularization in atherosclerotic conditions remains largely unknown. In the present report, we identified miR-150 as a proangiogenic miRNA which expression is significantly reduced in hypercholesterolemic conditions. This is associated with impaired Src signaling and inefficient neovascularization in response to ischemia. Our results also suggest that forced expression of miR-150 could constitute a novel therapeutic strategy to improve ischemia-induced neovascularization in atherosclerotic conditions.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Effect of Atherosclerotic Conditions on miRNA Expression
We used next-generation sequencing analyses to evaluate the expression of miRNAs in the ischemic muscles of hypercholesterolemic apolipoprotein E-deficient (ApoE −/− ) mice and in normocholesterolemic control mice. miRNAs that were significantly expressed in hindlimb muscles (at least 1000 reads per million reads mapped) and that were modulated by 20% or more were selected. As seen on Figure 1A and Figure I in the online-only Data Supplement, hypercholesterolemia was mainly associated with a downregulation of miRNAs in ischemic muscles. Ten miRNAs were found to be upregulated, but the 8 miRNAs most strongly upregulated are specific to mice and not found in humans. Among downregulated miRNAs, miR-150 showed the most important modulation in the ischemic muscles of ApoE −/− mice ( Figure 1A ; Figure I in the online-only Data Supplement). miR-150 is present in mammals, including mice and humans. Using reverse transcription polymerase chain reaction, we found that the expression of miR-150 in muscles is reduced after ischemia. Moreover, the expression of miR-150 is significantly impaired in hypercholesterolemic ApoE −/− mice, both in nonischemic and ischemic muscles ( Figure 1B ). The expression of miR-150 is also significantly reduced in human umbilical vein endothelial cells (HUVECs) exposed to oxidized low-density lipoprotein (oxLDL; Figure 1C ), but not in HUVECs exposed to native low-density lipoprotein ( Figure II in the online-only Data Supplement). miR-150 transcription has been shown to be repressed by p53. 18 Our results indicate that p53 is activated in the ischemic muscles of hypercholesterolemic ApoE −/− mice and in HUVECs exposed to oxLDL ( Figure III in the onlineonly Data Supplement). This suggests that hypercholesterolemia and oxLDL could downregulate miR-150 at least in part via p53. Interestingly, miR-150 was previously shown to enhance endothelial cell migration in vitro. 19 Therefore, in the following experiments, we focused on characterizing the specific role of miR-150 in the modulation of angiogenesis and neovascularization in atherosclerotic/hypercholesterolemic conditions. miRNA mimic. Transfection efficiency was established to be >80%, as assessed using a labeled miRNA mimic control (data not shown). As seen in Figure 2A and 2C, exposure to oxLDL (but not native low-density lipoprotein; Figure II in the onlineonly Data Supplement) reduced tube formation in HUVECs. However, treatment with miR-150 significantly improved tube formation in HUVECs exposed to oxLDL. In addition, miR-150 completely rescued oxLDL-induced impairment of cell migration in HUVECs ( Figure 2B and 2D).
miR-150 Rescues oxLDL-Induced Impairment of Angiogenesis in Endothelial Cells
Effect of miR-150 on Ischemia-Induced Neovascularization in Atherosclerotic Conditions
Hindlimb perfusion was evaluated after surgically induced ischemia by serial Laser Doppler perfusion imaging studies ( Figure 3A and 3B). Compared with controls, blood flow recuperation was significantly impaired in hypercholesterolemic ApoE −/− mice at day 14 after surgery (Doppler flow ratio 0.39±0.03 versus 0.55±0.05; P<0.05). However, ApoE −/− mice treated intramuscularly with a miR-150 mimic showed dramatic improvements of perfusion (0.71±0.07 versus 0.39±0.03; P<0.05) and were, therefore, completely protected against hypercholesterolemia-induced impairment of blood flow recuperation ( Figure 3B ). Clinically, this was correlated with a reduction of ambulatory impairment in mice treated with miR-150 mimic ( Figure 3C ). A similar effect was observed at the microvascular level. Hypercholesterolemic ApoE −/− mice exhibited reduced capillary and arteriolar densities in ischemic muscles ( Figure 3D through 3F). However, intramuscular treatment with miR-150 mimic significantly increased vascular densities in the ischemic muscles of ApoE −/− mice.
miR-150 Rescues the Number and the Functional Activities of PACs
PACs have been shown to reach sites of neovascularization where they can contribute to the formation of new blood vessels. 5 However, the number and the functional activities of PACs are impaired in patients presenting atherosclerotic conditions, including hypercholesterolemia. 15 Here we found that the number of bone marrow-derived PACs is significantly reduced in hypercholesterolemic ApoE 
miR-150 Promotes Angiogenesis via Activation of Src Pathway
miR-150 has previously been shown to directly target SRC kinase signaling inhibitor 1 (SRCIN1), an important regulator of Src activity. 20 Src is a tyrosine kinase that is known to be required during VEGF-induced angiogenesis and vascular permeability. 7 Here we found that SRCIN1 expression is significantly increased in the ischemic muscles of hypercholesterolemic ApoE −/− mice ( Figure 5A and 5B). This is associated with a reduced activation of Src, together with an inhibition of Src downstream signaling, including Akt and eNOS. Interestingly, Src angiogenic pathway is completely restored in ApoE −/− mice that are treated with a miR-150 mimic ( Figure 5A and 5B). Similar findings are also observed in HUVECs, where exposure to atherosclerotic oxLDL leads to increased expression of SRCIN1 and inhibition of Src, Akt, and eNOS activities ( Figure 5C ). However, miR-150 treatment can reduce SRCIN1 expression and restore Src signaling pathway in HUVECs exposed to oxLDL ( Figure 5D ). We found that the angiogenic activities of miR-150 in HUVECs (tube formation and cell migration) are abolished when the cells are also treated with the specific Src kinase inhibitor SKI-1 ( Figure 5E and 5F). In addition, inhibition of miR-150 using an anti-miR increases SRCIN1 expression and reduces endothelial cell migration and tube formation ( Figure 6A and 6B ). We also demonstrate that similarly to miR-150 induction, downregulation of SRCIN1 using siRNA can restore Src pathway and angiogenic functions (migration, tube formation) in endothelial cells exposed to oxLDL ( Figure 6C and 6D) . Our data also suggest that Src pathway is involved in PACs because we found that isolated PACs exposed to oxLDL exhibit increased expression of SRCIN1 and impaired activation of Src that can be rescued by forced expression of miR-150 (see Figure IV in the online-only Data Supplement). 
Discussion
To our knowledge, the present study is the first one to document the effect of hypercholesterolemia on the modulation of miRNAs in ischemic tissues. It is also the first demonstration of the essential role of a miRNA (miR-150) for the modulation of angiogenesis and ischemia-induced neovascularization during atherosclerotic conditions. Although miRNAs are increasingly recognized as essential factors involved in a variety of physiological processes, their specific role for the modulation of neovessel development during different pathological conditions remains to be defined. Moreover, the effect of cardiovascular risk factors on the expression levels of miRNAs and how this might influence the angiogenic response after ischemia are currently unknown. Patients with atherosclerotic diseases often exhibit several conditions that have been shown to impair neovascularization in response to ischemia.
1 This could at least in part explain the lack of efficacy of proangiogenic therapies in atherosclerotic patients, compared with the positive results obtained in young and healthy animals. 21 Hypercholesterolemia is one of the most important conditions associated with the development of atherosclerotic diseases. It is involved in the initiation and growth of the atherosclerotic lesion, which progressively causes vascular obstruction, leading to acute or chronic tissue ischemia. 22 On the other hand, hypercholesterolemia has also been associated with defective reparative processes occurring in response to ischemia. For instance, reduced ischemia-induced neovascularization has been described in several hypercholesterolemic animal models. [12] [13] [14] 23 Moreover, the number and the functional activities of PACs are reduced in hypercholesterolemic patients with or without clinically apparent atherosclerotic diseases. 15, 24 However, the specific mechanisms that are involved in the inhibition of neovascularization and PAC function by hypercholesterolemia are not completely understood. The present study uncovered a novel mechanism by which modulation of miRNA expression could contribute to inhibit ischemiadependent reparative responses in hypercholesterolemic conditions. It demonstrates for the first time that reduced expression of miR-150 in atherosclerotic conditions leads to impairment of neovascularization and blood flow recuperation after tissue ischemia.
miR-150 is evolutionarily conserved and found in mammals, including mice and humans.
Recent evidence suggests that miR-150 is involved in the regulation of embryogenesis, 25 as well as normal and malignant hematopoiesis. 26 miR-150 has also been shown to promote the proliferation and migration of cancer cells 20 and is thought to play an important role in solid tumors. 27 Interestingly, miR-150 was recently shown to be involved in endothelial cell differentiation and vasculogenesis. 28 In the current study, we demonstrate that miR-150 is also crucial for the physiological response to tissue ischemia in atherosclerotic conditions. We found that the expression of miR-150 is reduced both in endothelial cells exposed to oxLDL and in the ischemic muscles of hypercholesterolemic mice. Although we did not specifically investigate the mechanism(s) involved in the downregulation of miR-150, it was previously shown that p53 binds to regulatory sequences in the upstream of miR-150 and represses its transcription. 18 We found that p53 is activated in the ischemic muscles of hypercholesterolemic ApoE −/− mice and in HUVECs exposed to oxLDL. This suggests that hypercholesterolemia and oxLDL could downregulate miR-150 at least in part via p53. Interestingly, the expression of miR-150 is reduced in the serum of hypercholesterolemic patients 29 and in patients with coronary artery diseases. 30 In the current study, supplementation of miR-150 with a miR mimic could restore the angiogenic properties of endothelial cells exposed to oxLDL. More importantly, using a well-characterized model of hindlimb ischemia, we show that miR-150 supplementation could have important therapeutic effects in the setting of ischemia. Hypercholesterolemic animals treated with miR-150 demonstrated significant improvement of blood flow recovery and overall mobility compared with controls. At the microvascular level, this was associated with increased capillary and arteriolar densities in ischemic muscles of treated animals. These proangiogenic effects of miR-150 are consistent with previous studies demonstrating that secreted monocytic miR-150 enhances endothelial cell migration in vitro 19 and promotes angiogenesis in vivo in a matrigel plug assay. 31 Neutralization of miR-150 has also been shown to reduce angiogenesis and tumor development in vivo. 32 On the other hand, other studies have reported that miR-150 could have antiangiogenic effects in specific conditions, such as poststroke cerebral angiogenesis 33 and pathological ocular neovascularization. 34 Globally, these results indicate that the physiological effects of miR-150 might vary according to the pathological situation and the specific cell type studied.
The mechanism by which miR-150 modulates angiogenesis and neovascularization after ischemia seems to involve Src pathway. One of the direct targets of miR-150 is SRCIN1. 20 SRCIN1, also known as p140CAP (p140 Cas-associated protein), is an important regulator of Src. It can shift the balance from active to inactive Src by phosphorylating the inhibitory Tyr527. 35 In cancer cells, the silencing of SRCIN1 favors cell proliferation, motility, and invasion in vitro, as well as tumor growth in vivo. 35 Interestingly, miR-150 was recently shown to promote the proliferation and migration of lung cancer cells by targeting SRCIN1 20 . The specific role of SRCIN1 in angiogenesis and ischemia-induced neovascularization is unknown. However, Src is recognized as an important modulator of VEGF-induced angiogenesis. 7 Moreover, Src activation can stimulate other important pathways that are involved in angiogenesis and neovascularization, such as PI3K/Akt and eNOS. 9 In the current study, we found that reduced miR-150 levels correlated with increased expression of SRCIN1 in the ischemic muscles of hypercholesterolemic mice and in HUVECs exposed to oxLDL. Increased levels of SRCIN1 were in turn associated with a significant reduction of phosphorylated Src. Importantly, miR-150 treatment could reduce SRCIN1 expression and restore Src activity, both in vitro and in vivo. We also demonstrate that miR-150 supplementation can stimulate Src/Akt/eNOS pathways and improve angiogenesis and neovascularization in these conditions. The importance of Src pathway is also illustrated by the fact that a direct inhibitor of Src abolished the proangiogenic activities of miR-150 in endothelial cells. We also found that inhibition of miR-150 increases SRCIN1 expression and reduces endothelial cell migration and tube formation. Moreover, similarly to miR-150 induction, downregulation of SRCIN1 using siRNA can restore Src pathway and angiogenic functions in endothelial cells exposed to oxLDL. Taken together, our results suggest that reduced expression of miR-150 in atherosclerotic conditions increases SRCIN1 levels, which leads to impaired Src activity and defective angiogenesis. It is important to recognize, however, that miRNAs may have dozens or even hundreds of targets. Therefore, our study does not rule out the possibility that apart from SRCIN1, other factors could contribute to the proangiogenic effects of miR-150. For instance, in other experimental conditions, miR-150 has previously been shown to promote angiogenesis by directly or indirectly modulating targets such as c-myb 19 and VEGF. 32 The results of the present study suggest that PACs could also be involved in the modulation of neovascularization by miR-150. PACs have been shown to reach ischemic tissues where they can improve neovascularization either directly by incorporating into new vessels or more often indirectly through paracrine secretion of angiogenic growth factors. 5 Here we found that both the number and the functional activities of PACs were reduced in hypercholesterolemic mice. However, treatment with miR-150 mimic after surgically induced hindlimb ischemia could restore the number and the functional activities of PACs (migration, adhesion, integration into tubules) in these animals. miRNAs are increasingly recognized as important regulators of stem and progenitor cells. 36 The stimulating effect of miR-150 on PACs in the current study is consistent with previous reports demonstrating the importance of this miRNA for the development of cell lineages involved in immune response 37 and vascular development. 28 The specific mechanisms responsible for the modulation of PAC functions by miR-150 remain to be determined. Isolated PACs exposed to oxLDL exhibit increased expression of SRCIN1 and impaired activation of Src that can be rescued by forced expression of miR-150. Therefore, similarly to what was found in mature endothelial cells, it is possible that Src pathway is also involved in the modulation of PACs by miR-150. For instance, a critical role of Src family kinase was recently described in SDF-1 (stromal-derived-factor-1)/CXCR4 (C-X-C chemokine receptor type 4)-mediated bone marrow progenitor cell recruitment to the ischemic heart. 38 Moreover, Src can activate eNOS, 9 a factor that has been shown to have an essential role for the modulation of PAC number and function. 39 Therefore, it is plausible that miR-150 improves PAC functions by stimulating Src pathway, an effect that could be impaired in atherosclerotic conditions, such as hypercholesterolemia.
In conclusion, our study demonstrates for the first time that reduced miR-150 expression contributes to reduce angiogenesis and ischemia-induced neovascularization in atherosclerotic conditions. The mechanism involves increased expression of SRCIN1, downstream inhibition of the angiogenic Src pathway, together with impaired angiogenic activities of mature endothelial cells and PACs. Our results also suggest that forced expression of miR-150 using a miR mimic could constitute a novel therapeutic strategy to improve ischemia-induced neovascularization in atherosclerotic conditions, such as hypercholesterolemia.
